Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHLORDIAZACHEL vs A-POXIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Anxiety disorders,Acute alcohol withdrawal,Preoperative anxiety,Irritable bowel syndrome (off-label),Panic disorder (off-label)
Anxiety disorders,Alcohol withdrawal syndrome,Seizure disorders (adjunctive),Preoperative sedation
Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
Parent: 5-30 hours (mean 15 hours); active metabolite desmethylchlordiazepoxide: 10-20 hours; further metabolite demoxepam: 24-96 hours; clinical context: causes drug accumulation with chronic dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (Cr Cl < 50 m L/min).
Chlordiazepoxide is metabolized in the liver primarily by CYP3A4 and CYP2D6 enzymes. Its active metabolites include desmethylchlordiazepoxide, demoxepam, and nordazepam.
Extensively metabolized in the liver via CYP2C19 (major) and CYP3A4 (minor) to inactive metabolites. CYP2C19 polymorphisms significantly affect clearance.
Renal: 50-70% as metabolites (mainly oxazepam and desmethylchlordiazepoxide); biliary/fecal: 10-20% as glucuronide conjugates; 1-2% excreted unchanged.
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
90-98% bound to albumin and alpha-1-acid glycoprotein.
95% bound to albumin.
0.5-0.8 L/kg; high Vd indicates extensive tissue distribution, with accumulation in adipose and brain tissue.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water with accumulation in tissues (brain, liver, kidneys).
Oral: 90-100% (well absorbed); IM: 80-100% (but variable due to precipitation at injection site); IV: 100%.
Oral: 80-90%; Intramuscular: 95-100%; no data for other routes.
GFR 10-50 m L/min: administer 50-100% of usual dose; GFR <10 m L/min: administer 25-50% of usual dose.
No dosage adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), maximum dose 20 mg daily.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
Mild impairment: no adjustment. Moderate-to-severe (Child-Pugh B/C): maximum dose 20 mg daily.
Children 6-12 years: 5 mg orally 2-4 times daily, max 30 mg/day. Not recommended under 6 years.
Approved for GERD in children ≥1 year (weight-based: 0.5-1 mg/kg once daily; maximum 20 mg). Safety in infants <1 year not established.
Initial: 5 mg orally 1-2 times daily, increase cautiously; reduce total daily dose by 50% compared to younger adults.
No specific dose adjustment, but monitor renal function and for increased risk of Clostridium difficile infection and osteoporosis-related fractures.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve use for patients with inadequate alternatives.
Risk of dependence and withdrawal reactions,Potential for abuse and addiction,Respiratory depression, especially with concomitant CNS depressants,Central nervous system depressant effects, caution with impaired hepatic or renal function,Paradoxical reactions (e.g., agitation, aggression) in psychiatric patients,Suicidal ideation and behavior,Use in pregnancy: risk of neonatal sedation and withdrawal,Elderly patients: increased sensitivity and risk of falls
Risk of dependence and withdrawal reactions; avoid abrupt discontinuation. May cause CNS depression and impair cognitive function. Use caution in hepatic impairment and geriatric patients.
Hypersensitivity to chlordiazepoxide or any benzodiazepine,Severe respiratory insufficiency,Sleep apnea syndrome,Severe hepatic impairment,Myasthenia gravis,Acute narrow-angle glaucoma,Concomitant use with ketoconazole, itraconazole, or other strong CYP3A4 inhibitors
Severe hepatic impairment, acute narrow-angle glaucoma, myasthenia gravis, hypersensitivity to benzodiazepines, concurrent use with potent CYP3A4 inhibitors.
Avoid alcohol. No specific food interactions; take with or without food. Limit caffeine if it worsens symptoms.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Avoid alcohol. Taking with food may delay absorption but does not affect total bioavailability.
First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless benefit justifies risk.
First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. Chronic use: Fetal hydantoin syndrome (craniofacial anomalies, growth deficiency, intellectual disability).
Excreted in breast milk; M/P ratio 0.25-0.5. Potential for infant sedation, poor feeding. Avoid breastfeeding or use alternative therapy.
Excreted into breast milk; M/P ratio ~0.3-0.5. Infant serum levels may reach subtherapeutic concentrations. Risk of sedation and poor feeding. Consider risk-benefit; monitor infant for drowsiness and weight gain.
Pregnancy may reduce plasma concentrations due to increased volume of distribution and enhanced clearance. Dose increases may be required, but avoid in pregnancy; if necessary, use lowest effective dose and limit duration.
Enhanced clearance (up to 50% increase) in pregnancy requires dose adjustments to maintain therapeutic levels. Frequent monitoring of free phenytoin levels recommended; total levels may be misleading due to decreased albumin. Postpartum dose reduction likely needed.
CHLORDIAZACHEL is a combination of chlordiazepoxide (benzodiazepine) and clidinium (anticholinergic). Used for peptic ulcer and irritable bowel syndrome. Monitor for CNS depression and anticholinergic effects (dry mouth, blurred vision, constipation). Avoid in glaucoma, urinary retention, and myasthenia gravis. Discontinue gradually to prevent withdrawal.
A-POXIDE is a potent benzodiazepine with rapid onset; use lowest effective dose to minimize tolerance. Monitor for respiratory depression, especially in elderly or those with COPD. Abrupt discontinuation may cause withdrawal seizures; taper gradually over weeks to months. Avoid concurrent use with other CNS depressants including alcohol.
Take exactly as prescribed; do not increase dose or duration.,Avoid alcohol and other CNS depressants.,May cause drowsiness; do not drive or operate machinery until effects are known.,Report bothersome side effects like constipation, dry mouth, or blurred vision.,Do not stop suddenly; taper under medical supervision.,Inform all healthcare providers you are taking this medication.
Do not consume alcohol while taking this medication.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Do not stop taking abruptly; follow your doctor's instructions for tapering the dose.,Inform your doctor if you have a history of substance abuse or respiratory conditions.,Store at room temperature away from moisture and heat.,Take exactly as prescribed; do not increase dose without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHLORDIAZACHEL vs A-POXIDE, answered by our medical review team.
CHLORDIAZACHEL is a Benzodiazepine that works by Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.. A-POXIDE is a Benzodiazepine that works by GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHLORDIAZACHEL and A-POXIDE depend on the specific clinical indication. These are both Benzodiazepine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHLORDIAZACHEL is: Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.. The standard adult dose of A-POXIDE is: GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHLORDIAZACHEL and A-POXIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHLORDIAZACHEL is classified as Category C. First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless . A-POXIDE is classified as Category C. First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonata. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.